Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transgene Secures Two Year Runway As Oncolytic Vaccine Enters Phase III

This article was originally published in Scrip

Executive Summary

Transgene SA's share price has received a welcome boost this week on two separate pieces of news. Transgene's development partner SillaJen Inc. has begun the first Phase III trial of the oncolytic immunotherapy Pexa-Vec in patients with advanced liver cancer. Also, the company unveiled a new strategic development plan as well as the securing of €30m new financing.


Related Content

Transgene’s Moment Of Truth Approaches
NICE Clears Amgen’s Imlygic At Second Attempt, Combo Results Keenly Awaited


What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts